Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04513925 | A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)(SKYSCRAPER-03) | completed | Phase 3 | 829 | Hoffmann-La RocheINDUSTRY | 26 | Jun 3, 2026 | clinicaltrials |
| NCT04619797 | A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(SKYSCRAPER-06) | completed | Phase 2 / Phase 3 | 542 |
| Hoffmann-La RocheINDUSTRY |
| 21 |
| Jun 3, 2026 |
| clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT05549037 | Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC(LungTIME-C01) | completed | Phase 3 | 210 | Hunan Province Tumor HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04881045 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | completed | Phase 1 | 29 | PfizerINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT02781857 | Mass Spectral Fingerprinting in Lung Cancer | completed | — | 309 | University of ZurichOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05162170 | Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study | completed | — | 633 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01421953 | Assessment of 4D 18F-FDG PET-CT in Radiotherapy for Non Small Cell Lung Cancers(PULMOTEP) | completed | N/A | 7 | University Hospital, BordeauxOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT02075840 | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants(ALEX) | completed | Phase 3 | 303 | Hoffmann-La RocheINDUSTRY | 29 | May 29, 2026 | clinicaltrials |
| NCT02688036 | Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC | completed | Phase 3 | 860 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06321510 | A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer. | completed | — | 29 | PfizerINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT05420220 | Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 95 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT05599685 | A Study of Nivolumab, Ipilimumab, and Chemotherapy in Participants With Non-small Cell Lung Cancer(AURORA) | completed | — | 302 | Bristol-Myers SquibbINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT00600496 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | completed | Phase 1 | 140 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT02959463 | Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma | completed | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04183218 | Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes | completed | — | 24 | Mayo ClinicOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05015608 | Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification(SACHI) | completed | Phase 3 | 216 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT04768075 | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC | completed | Phase 3 | 60 | Guangdong Association of Clinical TrialsOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05928299 | Integrative Multi-Omics Testing for Immunotherapy Response in Non-Small Cell Lung Cancer(IMOTION) | completed | — | 150 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02504489 | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC(DUBLIN-3) | completed | Phase 3 | 559 | BeyondSpring Pharmaceuticals Inc.INDUSTRY | 3 | May 19, 2026 | clinicaltrials |
| NCT06713564 | A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer | completed | Phase 1 | 24 | Integro TheranosticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT02438722 | S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 174 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 789 | Regeneron PharmaceuticalsINDUSTRY | 18 | May 18, 2026 | clinicaltrials |
| NCT00534690 | Does PEP Compensate the Reduction of Tidal Volume During One Lung Ventilation?(REVOLU) | completed | N/A | 88 | University Hospital, BordeauxOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05599321 | Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling | completed | — | 110 | Penn State UniversityOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06255041 | Detection of Cancer in Breath Samples by Trained Detection Dogs | completed | — | 1,386 | SpotitEarlyINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07590947 | Evaluation of the Utility of Rapid On-site Cytology Performed by an Interventional Pulmonologist During EBUS-TBNA.(ROSE) | completed | — | 189 | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di AlessandriaOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07591376 | A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers(APART-LUNG) | completed | N/A | 30 | University Hospital Schleswig-HolsteinOTHER | 2 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04087473 | Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC | completed | — | 50 | National Cancer Centre, SingaporeOTHER | 4 | May 13, 2026 | clinicaltrials |
| NCT05231278 | Confocal Laser Endomicroscopy Nodule Localization by Robotic Bronchoscopy(CLEAR) | completed | N/A | 53 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05617742 | Comparison of 68Ga-FAPI-46 PET and 18F-FDG PET in Lung Cancer | completed | N/A | 58 | Chang Gung Memorial HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06145048 | Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.(VISUALIZE) | completed | Phase 2 | 89 | Vergent Bioscience, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT06939049 | Development of New Methodologies and Innovative Tools for the diagnoSi and Therapeutic Treatment of uMAni Epithelial Tumors(SISTEMA) | completed | — | 250 | ASL LecceOTHER_GOV | 1 | May 13, 2026 | clinicaltrials |
| NCT03758287 | Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative | completed | Phase 1 / Phase 2 | 108 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT04010357 | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04042558 | A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies(GFPC 06-2018) | completed | Phase 2 | 150 | Centre Francois BaclesseOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03607539 | Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC | completed | Phase 3 | 397 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT02399371 | Pembrolizumab in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 65 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04146064 | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response | completed | — | 190 | University Health Network, TorontoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT05453721 | Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane（IMPLANE-0529）(IMPLANE-0529) | completed | N/A | 272 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06576908 | Evaluation of On-Couch CBCT Image Quality | completed | N/A | 46 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT02314481 | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity(DARWINII) | completed | Phase 2 | 50 | University College, LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02496624 | Cone-beam CT Guided Microcoil Localization of Pulmonary Nodules During Video Assisted Thoracic Surgery(VATS) | completed | N/A | 40 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03563716 | A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 135 | Genentech, Inc.INDUSTRY | 6 | May 4, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 3, 2026source: clinicaltrials